JaxBio Technologies Receives $2.73 Million Funding Boost
19 July 2024•
%2Fuploads%2Fpr%2520articles%2F2024%2F07%2F19_6jaxbio.jpg&w=3840&q=75)
Medical diagnostics startup JaxBio Technologies, based in Netanya, Israel, was awarded a $2.73 million grant by the European Innovation Council (EIC) Accelerator.
This funding came with the possibility of future blended financing, meaning that another €9.1 million may come from the EU and another €9.1 million from private investors.
The company plans to utilise the money to build its diagnostics platform, extend clinical programmes, and develop a blood test that will make lung cancer diagnosis and treatment easier, faster, and more accurate.
Under the direction of Dr. Shahar Zirkin, the company’s founder and CEO, JaxBio is creating a blood test for accurate cancer and other disease diagnosis.
Its liquid biopsy method improves monitoring, therapy prediction, and diagnosis by detecting hundreds of cancer biomarkers in blood at a low cost and great sensitivity.
When time is of the essence, this lab technique yields results the next day, allowing healthcare practitioners and patients to make quicker, more informed decisions.
---
Send us your press releases to [email protected]
%2Fuploads%2Fhealthtech%2Fcover18.jpg&w=3840&q=75)
